149 related articles for article (PubMed ID: 8242617)
1. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Chang TK; Weber GF; Crespi CL; Waxman DJ
Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
[TBL] [Abstract][Full Text] [Related]
2. Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs.
Soucek P; Zuber R; Anzenbacherová E; Anzenbacher P; Guengerich FP
BMC Pharmacol; 2001; 1():11. PubMed ID: 11737866
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of cytochromes P450 2B in rat liver by orphenadrine.
Murray M; Fiala-Beer E; Sutton D
Br J Pharmacol; 2003 Jun; 139(4):787-96. PubMed ID: 12813002
[TBL] [Abstract][Full Text] [Related]
4. Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study.
Dabbish E; Scoditti S; Shehata MNI; Ritacco I; Ibrahim MAA; Shoeib T; Sicilia E
J Comput Chem; 2024 Apr; 45(10):663-670. PubMed ID: 38088485
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models-A Prelude to Treating Solid Tumours Effectively in Pets and Humans.
Salmons B; Gunzburg WH
Life (Basel); 2023 Dec; 13(12):. PubMed ID: 38137959
[TBL] [Abstract][Full Text] [Related]
6. Maximizing ovarian function and fertility following chemotherapy in premenopausal patients: Is there a role for ovarian suppression?
Roof KA; Andre KE; Modesitt SC; Schirmer DA
Gynecol Oncol Rep; 2024 Jun; 53():101383. PubMed ID: 38633671
[TBL] [Abstract][Full Text] [Related]
7. The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma.
Picher EA; Wahajuddin M; Barth S; Chisholm J; Shipley J; Pors K
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473371
[TBL] [Abstract][Full Text] [Related]
8. Anti-Cancer Prodrug Cyclophosphamide Exerts Thrombogenic Effects on Human Venous Endothelial Cells Independent of CYP450 Activation-Relevance to Thrombosis.
Krüger-Genge A; Köhler S; Laube M; Haileka V; Lemm S; Majchrzak K; Kammerer S; Schulz C; Storsberg J; Pietzsch J; Küpper JH; Jung F
Cells; 2023 Jul; 12(15):. PubMed ID: 37566045
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of chemotherapy in cancer patients with different ethnicities.
Pathak S; Zajac KK; Annaji M; Govindarajulu M; Nadar RM; Bowen D; Babu RJ; Dhanasekaran M
Cancer Rep (Hoboken); 2023 Sep; 6 Suppl 1(Suppl 1):e1830. PubMed ID: 37150853
[TBL] [Abstract][Full Text] [Related]
10. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.
Marie S; Frost KL; Hau RK; Martinez-Guerrero L; Izu JM; Myers CM; Wright SH; Cherrington NJ
Acta Pharm Sin B; 2023 Jan; 13(1):1-28. PubMed ID: 36815037
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics in Children.
Rieder MJ; Elzagallaai AA
Methods Mol Biol; 2022; 2547():569-593. PubMed ID: 36068477
[TBL] [Abstract][Full Text] [Related]
12. The cytotoxicity of cyclophosphamide is enhanced in combination with monascus pigment.
Kurokawa H; Taninaka A; Shigekawa H; Matsui H
J Clin Biochem Nutr; 2021 Sep; 69(2):131-136. PubMed ID: 34616104
[TBL] [Abstract][Full Text] [Related]
13. Inter-ethnic genetic variations and novel variant identification in the partial sequences of
Ahmed S; Khan H; Khan A; Bangash MH; Hussain A; Qayum M; Hamdard MH
PeerJ; 2021; 9():e11149. PubMed ID: 34386299
[TBL] [Abstract][Full Text] [Related]
14. Porphylipoprotein Accumulation and Porphylipoprotein Photodynamic Therapy Effects Involving Cancer Cell-Specific Cytotoxicity.
Kurokawa H; Ito H; Matsui H
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298933
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.
Pinto N; Navarro SL; Rimorin C; Wurscher M; Hawkins DS; McCune JS
Pediatr Blood Cancer; 2021 Nov; 68(11):e29203. PubMed ID: 34245211
[TBL] [Abstract][Full Text] [Related]
16. Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer.
Amioka A; Kadoya T; Sueoka S; Kobayashi Y; Sasada S; Emi A; Masumoto N; Ito M; Nakayama K; Okada M
Breast Cancer; 2021 Sep; 28(5):1062-1071. PubMed ID: 34047951
[TBL] [Abstract][Full Text] [Related]
17. Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers.
Pidkovka N; Rachkevych O; Belkhiri A
Oncotarget; 2021 Feb; 12(4):379-391. PubMed ID: 33659048
[TBL] [Abstract][Full Text] [Related]
18. Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population.
Ahmed S; Khan S; Janjua K; Imran I; Khan AU
Mol Genet Genomic Med; 2021 Mar; 9(3):e1527. PubMed ID: 33599403
[TBL] [Abstract][Full Text] [Related]
19. Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.
Rendic SP; Guengerich FP
Arch Toxicol; 2021 Feb; 95(2):395-472. PubMed ID: 33459808
[TBL] [Abstract][Full Text] [Related]
20. PharmVar GeneFocus: CYP2B6.
Desta Z; El-Boraie A; Gong L; Somogyi AA; Lauschke VM; Dandara C; Klein K; Miller NA; Klein TE; Tyndale RF; Whirl-Carrillo M; Gaedigk A
Clin Pharmacol Ther; 2021 Jul; 110(1):82-97. PubMed ID: 33448339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
